TC BioPharm Announces Plans for Monkey Pox Treatment Studies
TC BioPharm plans pre-clinical studies for Monkey Pox treatment with TCB 008, an unmodified cell therapy using gamma delta T cells. The company also progresses ACHIEVE Phase 2b trial for AML/MDS-AML with TCB008, and secures a European patent for modified delta cells in cancer and viral treatments.
Highlighted Terms
Related News
TC BioPharm Announces Plans for Monkey Pox Treatment Studies
TC BioPharm plans pre-clinical studies for Monkey Pox treatment with TCB 008, an unmodified cell therapy using gamma delta T cells. The company also progresses ACHIEVE Phase 2b trial for AML/MDS-AML with TCB008, and secures a European patent for modified delta cells in cancer and viral treatments.